Biohit Oyj - Company Announcement

Biohit Oyj to strengthen its Nordic diagnostic distribution

Biohit Oyj March 26, 2013 at 2 P.M. local time (EET)



Finnish health care company Biohit Oyj has signed a distributor agreement with
Fischer Scientific AB. The agreement covers the distribution and marketing of
Biohit's diagnostic products in Finland, Sweden, Norway and Denmark. 

Agreement will strengthen the distribution of diagnostic products by Biohit.
Co-operation will continue also with previously signed distributor partners,
Euro-Diagnostica AB and Electra-Box Diagnostica AB. 

CEO Semi Korpela, Biohit Oyj:  ”We are pleased that a major player in this
field recognizes the opportunities of our diagnostic products.” 

General Manager Peter Sandberg, Fisher Scientific AB: ”Biohit products are an
excellent complement in our existing product portfolio.” 



Additional information:

CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohit.fi



Biohit in brief

Biohit Oyj is a Finnish biotechnology company operating globally that was
established in 1988. Biohit's mission is "Innovating for Health". The purpose
of the company is to take social responsibility and produce innovation, new
technologies and analysis systems for use in medicine, research institutions
and industry, helping to promote research and diagnostics and to improve the
quality of life of people by means of preventing disease, human suffering and
financial loss. We are committed to social responsibility and it is our duty to
spread knowledge about the Group 1 human carcinogen, acetaldehyde, and innovate
and develop the marketing and availability of our products and services. Biohit
is headquartered in Helsinki and its subsidiaries are located in China and the
United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed
in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. 



Fisher Scientific in brief

Fisher Scientific is part of international Thermo Fisher Scientific Group. We
operate with high-quality products from well-known manufacturers and we act
with several research areas such as molecular biology, immunology, microbiology
and cell cultures. Our product portfolio includes chemicals, reagents,
consumable, and equipment. 
For more information: www.fishersci.se



Additional information about the GastroPanel examination:

Biohit Oyj has developed the GastroPanel biomarker tests, a unique blood sample
examination for the screening and diagnosis of Helicobacter pylori infection
and damage or dysfunction of the mucous membrane (atrophic gastritis) of the
stomach. Unlike the H. pylori examinations still being used (13C urea breath
test and stool antigen test), the GastroPanel tests reliably detect the H.
pylori infection, the typically asymptomatic condition atrophic gastritis, and
associated risks, including cancer. 

The April 2012 Maastricht IV consensus report of the European Helicobacter
Pylori Study Group recommends blood sample biomarker tests as a reliable method
of diagnosis of diseases of the stomach mucosa and associated risk conditions.
Researchers recommend biomarker tests for the diagnosis and follow-up of
Helicobacter pylori infection and especially for atrophic gastritis that causes
achlorhydric stomachs, as well as to the screening of asymptomatic patients.
The report emphasises the fact that H. Pylori eradication therapy does not cure
precancerous gastric conditions. This is why gastroscopy and biopsy
examinations are recommended at regular intervals of 2-3 years for patients
with moderately severe or severe atrophic gastritis. Without gastroscopy and
biopsy examination, atrophic gastritis in the entire stomach (precancerous
condition) and its location can only be diagnosed with a GastroPanel biomarker
test. 

The international Healthy Stomach Initiative group's 16 gastroenterology
experts from 12 countries came to the same conclusions. Biomarker tests can be
used to diagnose and screen atrophic gastritis and related risks in both
asymptomatic patients and patients with abdominal discomfort
(www.biohithealthcare.com: Investors/ Stock Exchange Releases: 17/02/2012
Biohit Oyj's GastroPanel biomarker test recommended). According to the
taskforce, GastroPanel biomarker tests, unlike the Helicobacter pylori
examination tests still in use, reliably diagnose the most significant risk
conditions of the acid-free stomach (atrophic gastritis). With the help of the
GastroPanel test, patients can be referred to appropriate further examinations,
therapy and treatment. At the same time it is also possible to reliably
diagnose patients who have a “healthy” stomach, i.e. patients who do not have
H. pylori infection and/or atrophic gastritis. 

 An IARC (WHO agency on cancer research) classification of October 2009 states
that acetaldehyde in alcoholic beverages and naturally generated in alcohol is
a group 1 carcinogen and is therefore as carcinogenic as H. pylori, asbestos,
formaldehyde and benzene. GastroPanel biomarker tests reliably detect an
anacidic stomach which is the major risk factor of gastric cancer. In addition,
recent studies show that acetaldehyde generated in an anacidic stomach is a
significant reason for gastric and oesophageal cancer risk associated with the
condition. Microbes from the mouth can colonise an acid-free stomach and
produce carcinogenic acetaldehyde from sugar and alcohol. According to gene
studies this is one of the major risk factors of gastric and oesophageal
cancer. The risk can be reduced with the help of another Finnish innovation -
prescription-free Acetium capsules, which are taken during food and alcohol
consumption, to bind (neutralise) carcinogenic acetaldehyde in the stomach. 



Literature:

1. Malfertheiner P et al. Management of Helicobacter pylori infection--the
Maastricht IV/ Florence Consensus Report. http://gut.bmj.com on May 18, 2012.
European H. pylori Study Group, ESPSG. 
2. Agréus L et al. Rationale in diagnosis and screening of atrophic gastritis
with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47:136-47. 
3. World Health Organisation WHO, 2009.
www.iarc.fr/en/media-centre/pr/2009/pdfs/pr196_E.pdf.